how many people are using glp-1 Here's Americans say they now taking drugs How Many People Take GLP-1

Description

Tirzepatide does not attack hair follicles

Dosing Protocol Key Efficacy Data The SURMOUNT clinical trial program established tirzepatide as the most effective GLP-1 weight loss agent currently available: SURMOUNT-1 (adults without diabetes): Mean weight loss of 20.9% (10 mg), 24.0% (15 mg) at 72 weeks versus 3.1% placebo (Jastreboff et al., NEJM , 2022) SURMOUNT-2 (adults with type 2 diabetes): Mean weight loss of 12.8% (10 mg), 14.7% (15 mg) at 72 weeks (Garvey et al., Lancet , 2023) SURMOUNT-3 (after intensive lifestyle intervention lead-in): Mean total weight loss of 26.6% with tirzepatide 15 mg (Wadden et al., Nature Medicine , 2023) SURMOUNT-4 (withdrawal study): Patients who discontinued tirzepatide after 36 weeks regained approximately two-thirds of lost weight by week 88, demonstrating the chronic disease nature of obesity and the need for ongoing treatment (Aronne et al., JAMA , 2024) Why Dual Agonism Matters The GIP receptor activation in tirzepatide produces additive effects beyond GLP-1 agonism alone

Celiac serology (tTG-IgA) may be checked to confirm dietary adherence and disease control

Not because of doubt in the molecule, but because of uncertainty around everything that comes after

Of these, two studies ( N = 16 and N = 46, respectively) observed a positive association between the use of exenatide, liraglutide or dulaglutide and weight loss as well as HbA1c at 16 weeks 149 and 1 year 150 , while for the smaller one ( N = 7) this association was not significant 148